May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Murine Model of Primary Ocular Lymphoma and Immunotherapy by Intravitreal Injection of Oligodeoxynucleotide
Author Affiliations & Notes
  • A. Scheffer
    University of Lille, Lille, France
    Ophthalmology-CHRU,
  • J. F. Mineo
    University of Lille, Lille, France
    Neurosurgery-CHRU,
  • A. Bordron
    Hematology-CHU, University of Brest, Brest, France
  • C. A. Maurage
    University of Lille, Lille, France
    Pathology-CHRU,
  • J. Trauet
    University of Lille, Lille, France
    Immunology-CHRU,
  • M. Hé. Gevaert
    University of Lille, Lille, France
    Histology-CHRU,
  • J. P. Dessaint
    University of Lille, Lille, France
    Immunology-CHRU,
  • M. Labalette
    University of Lille, Lille, France
    Immunology-CHRU,
  • P. Labalette
    University of Lille, Lille, France
    Ophthalmology-CHRU,
  • Footnotes
    Commercial Relationships A. Scheffer, None; J.F. Mineo, None; A. Bordron, None; C.A. Maurage, None; J. Trauet, None; M.H. Gevaert, None; J.P. Dessaint, None; M. Labalette, None; P. Labalette, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1579. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Scheffer, J. F. Mineo, A. Bordron, C. A. Maurage, J. Trauet, M. Hé. Gevaert, J. P. Dessaint, M. Labalette, P. Labalette; Murine Model of Primary Ocular Lymphoma and Immunotherapy by Intravitreal Injection of Oligodeoxynucleotide. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1579.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Human primary intraocular lymphoma (PIOL) is a lethal disease with only few effective therapies available. However, there is currently no animal model of B-cell PIOL in immunocompetent host permitting the evaluation of new therapeutic approaches. The purpose of this study is to establish a new murine model of B-cell PIOL in an immunocompetent host and to evaluate an immunotherapy method based on intravitreal injection of oligodeoxynucleotide (ODN).

Methods:: Lymphoma 38C13 B-cells were cultured in DMEM and then injected through the pars plana into the vitreous of immunocompetent C3H mice. Various amounts of these cells (ranging from 500 to 5000 cells per eye) were injected. ODN receptor (TLR9) expression was evaluated by an immunofluorescence method in eye and brain. ELISA tests were performed to compare two different ODN on their ability to induce cytokine secretion (IL-6 and TNF-α). Finally, the most effective (B type) was tested for its therapeutical effect by intravitreal injection.

Results:: Our murine model mimics human PIOL. Pathological examinations revealed that the tumor cells colonized the retina from the inner to the outer layers. TLR9 expression was visualized by immunofluorescence staining in the brain and the inner retinal layer. Intravitreal injection of ODN induced lymphocytic and macrophagic vitreous infiltration which abrogate retinal colonization.

Conclusions:: We built a new murine model of B-cell PIOL in immunocompetent host that globally mimics human PIOL. In addition, we work out the bases of an immunotherapy method by intravitreal injection of ODN.

Keywords: pathology: experimental • oncology • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×